Core Insights - Dyadic International, Inc. has received a $3 million grant from the Gates Foundation to develop monoclonal antibodies targeting respiratory syncytial virus (RSV) and malaria using its proprietary C1 protein production platform [1][4]. Group 1: Company Overview - Dyadic International, Inc. is a biotechnology company focused on the efficient large-scale manufacture of proteins for human and animal vaccines and therapeutics, as well as non-pharmaceutical applications [6]. - The C1 protein production platform is based on an industrially proven microorganism designed to accelerate development, reduce production costs, and improve scalability and performance of biologic vaccines and therapeutics [5][7]. Group 2: Health Impact - RSV is a significant cause of lower respiratory tract infections in children, leading to 3.2–36 million hospitalizations and over 100,000 deaths annually, predominantly in low-income and middle-income countries [2]. - In 2022, there were approximately 249 million malaria cases and 608,000 deaths globally, with the WHO African Region accounting for 94% of cases and 95% of deaths [2]. Group 3: Grant Utilization - The grant will enhance the C1 platform to enable rapid and cost-effective production of high-quality monoclonal antibodies, aiming to improve global access to critical treatments for RSV and malaria [4]. - The initiative seeks to deliver affordable therapeutic solutions to address urgent global health challenges, particularly in underserved populations [4][3]. Group 4: Future Plans - Dyadic plans to commercialize successful research efforts through licensure, expanding access to affordable treatment options and reducing the global burden of infectious diseases [5].
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology